Science

Home / Sustainability / Health equity / Science

We're taking steps to ensure our genomics and clinical trials are representative of the populations we serve to develop more effective medicines.

Embedding health equity across our science

Genomics

We're transforming medicine discovery and development by ensuring our genomics data represents patients affected by disease, including those from often understudied communities such as Latino, Asian, African, and Middle Eastern descent.

This helps us better understand disease biology, discover biomarkers, identify new targets, and match patients to the right medicine. We gather data from clinical trials and collaborate with over 60 academic, industry, government, and non-profit organisations across 19 countries.

Clinical trials

We're ensuring our clinical trials are representative of the people most impacted by disease, to improve access to innovative therapies and ensure our medicines are effective in different populations. 

We are expanding to new clinical trial sites and working with community health organisations to raise awareness, build trust and increase clinical trial enrolment among underserved populations. We are also investing in strengthening expertise from principal investigators and collaborating with industry groups and regulatory agencies to create best practices for health equity in clinical trials.

Open innovation

We're enabling the re-use of our science, including expertise and technologies, to support open innovation and the development of new scientific breakthroughs.

Projects using our molecules have received more than $100 million in funding from grant agencies, resulting in scientific advances that have been showcased in over 100 journal publications. Over the past decade, we’ve supported scientific discoveries in more than 20 disease areas, including many beyond our core focus. We've also engaged in over 1,000 collaborations across 40 countries.

News

See our annual Sustainability Data Annex for performance measures and targets

Veeva ID: Z4-74573
Date of preparation: May 2025